Search

Your search keyword '"Mauri, Laura"' showing total 83 results

Search Constraints

Start Over You searched for: Author "Mauri, Laura" Remove constraint Author: "Mauri, Laura" Publication Type Magazines Remove constraint Publication Type: Magazines
83 results on '"Mauri, Laura"'

Search Results

1. Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program

2. 5 Medtronic

3. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial

5. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial

6. Lipid rafts and neurodegeneration: structural and functional roles in physiologic aging and neurodegenerative diseases

7. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial

9. Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control After Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial

10. Five-year outcomes of transcatheter reduction of significant mitral regurgitation in high-surgical-risk patients

12. One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial: A Randomized Clinical Trial

13. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vsaspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial

14. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention

15. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials

16. Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure])

17. Actualización ESC 2017 sobre el tratamiento antiagregante plaquetario doble en la enfermedad coronaria, desarrollada en colaboración con la EACTS

18. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial

19. Update on antithrombotic therapy after percutaneous coronary revascularisation

20. Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study

22. T Follicular Helper Cells Promote a Beneficial Gut Ecosystem for Host Metabolic Homeostasis by Sensing Microbiota-Derived Extracellular ATP

24. Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction

25. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery

26. Comparing Inverse Probability of Treatment Weighting and Instrumental Variable Methods for the Evaluation of Adenosine Diphosphate Receptor Inhibitors After Percutaneous Coronary Intervention

28. Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study

29. 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction

31. Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis

33. Evaluating the Generalizability of a Large Streamlined Cardiovascular Trial

34. Direct interaction, instrumental for signaling processes, between LacCer and Lyn in the lipid rafts of neutrophil-like cells

35. Instrumental Variable Analysis to Compare Effectiveness of Stents in the Extremely Elderly

36. The oxysterol–CXCR2 axis plays a key role in the recruitment of tumor-promoting neutrophils

37. A Prediction Model to Identify Patients at High Risk for 30-Day Readmission After Percutaneous Coronary Intervention

38. Repeat Revascularization After Contemporary Percutaneous Coronary Intervention

39. Risk Prediction for Adverse Events After Carotid Artery Stenting in Higher Surgical Risk Patients

40. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial

41. Sources of Hospital Variation in Short-Term Readmission Rates After Percutaneous Coronary Intervention

42. Statistical Analysis of Noncommensurate Multiple Outcomes

43. Bleeding Risk Comparing Targeted Low-Dose Heparin With Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention

44. Study Design of the CLOSURE I Trial

45. Six-Month Results of the NEVO RES-ELUTION I (NEVO RES-I) Trial

46. Predicting Restenosis of Drug-Eluting Stents Placed in Real-World Clinical Practice

47. Sphingolipidomics of A2780 human ovarian carcinoma cells treated with synthetic retinoids

48. Photoactivable sphingosine as a tool to study membrane microenvironments in cultured cells

49. Abstract 9972: Estimation of DAPT Study Treatment Effects in Contemporary Clinical Practice: Findings from the EXTEND-DAPT Study

50. Selected natural and synthetic retinoids impair CCR7‐ and CXCR4‐dependent cell migration in vitro and in vivo

Catalog

Books, media, physical & digital resources